Project Grant R01HL179359
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $707K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $701,842 to the University of South Florida to investigate the role of the CDK13 gene in the development of congenital heart defects. The research aims to develop genetic mouse and induced pluripotent stem cell models to understand how mutations in the CDK13 gene lead to cardiac pathologies associated with "congenital heart defects, dysmorphic facial...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $711,039 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital. The award supports research to determine the functions of the cardiac m6A methyltransferases METTL3 and METTL14 in early myocardial development, and whether their dysregulation contributes to the pathogenesis of fetal dilated cardiomyopathy (DCM). The proposed study leverages mouse...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- This Project Grant award, valued at $667,704.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to address hypertrophic cardiomyopathy (HCM), a genetic heart condition affecting 1 in 500 adults. The primary objective is to develop chemically inducible split base editors (SBE) that can precisely and controllably edit the MYBPC3 gene in the heart to correct mutations that cause HCM. The research aims to expand...
- This federal Project Grant award of $777,016.00 from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) supports research to functionally characterize genes and genetic variants associated with hypoplastic heart syndrome (HHS) in the Drosophila model organism. The University of Maryland, Baltimore is the primary awardee and will apply a high-throughput "gene replacement" approach to validate 386 genetic variants linked to HHS,...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...